ArticleDiabetology & metabolic syndrome2025
The association between insulin resistance assessed by estimated glucose disposal rate and stroke prevalence and mortality in non-diabetic people: evidence from two prospective cohorts.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe estimated glucose disposal rate (eGDR), serving as a measure of insulin resistance (IR), provides a simpler and more accessible method for assessing insulin sensitivity. However, its association with stroke and mortality in non-diabetic patients remains to be fully clarified.
methodsData from the National Health and Nutrition Examination Survey (NHANES) Study (2003-2014, n = 11,063, age ≥ 45) were examined. Participants with diabetes, coronary heart disease (CHD), or missing key data were excluded. eGDR was calculated based on waist circumference, hypertension status, and glycated hemoglobin (HbA1c). The primary outcomes were stroke prevalence and all-cause, cardiovascular, and cerebrovascular disease mortality. For stroke outcomes, a cross-sectional analysis was conducted and multivariate logistic regression was employed for assessment; whereas for all mortality outcomes, longitudinal analysis was performed using multivariate Cox proportional hazards models. The association between eGDR and these outcomes was investigated using Kaplan-Meier survival analysis, Cox proportional hazards regression models, restricted cubic splines (RCS), and mediation analysis, adjusted for demographic and clinical variables. An additional cohort of 6,873 participants from the China Longitudinal Health and Aging Study (CHARLS) was applied to evaluate the association further.
resultsBetween 2003 and 2014, the NHANES study documented 380 stroke cases. A higher eGDR showed a significant linked to lower stroke prevalence (OR 0.44, 95% CI: 0.31-0.62, P < 0.001), as well as reduced all-cause mortality (HR 0.78, 95% CI: 0.68-0.89), CVD mortality (HR 0.70, 95% CI: 0.53-0.94) and cerebrovascular diseases mortality (HR 0.54, 95% CI: 0.31-0.94) over a median 117.6 months. Each one-unit increase in eGDR was associated with a 15% decrease in stroke prevalence (OR 0.85, 95% CI 0.79-0.9). The protective impact of a higher eGDR against stroke was consistently observed across most subgroups, but significantly stronger in individuals < 60 years. CHARLS demonstrated the research findings.
conclusionsElevated eGDR levels showed an independent correlation with a significantly reduced prevalence of stroke and decreased risks of mortality in non-diabetic adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.